Peptide yy pharmaceutical formulations, compositions, and methods

Abstract

Pharmaceutical compositions comprising PYY (e.g., PYY(3-36) and analogs and variants thereof), satiety peptides, satiety hormones, metabolic hormones, and methods of treating metabolic diseases with such compositions are provided. Aspects include methods of increasing a feeling of fullness in patients treated with pharmaceutical compositions comprising PYY, PYY(3-36), satiety peptides, satiety hormones, metabolic hormones, and analogs, receptor antagonists and variants thereof.

1 . A pharmaceutical composition comprising glucagon-like peptide 1 (GLP-1) in a dose of from about 2.5 ng to about 2.5 mg, wherein the composition provides satiation to a subject without substantially changing the concentration of GLP-1 in the plasma of the subject, and wherein the composition is formulated as an oral dissolving tablet. 
     
     
         2 . The pharmaceutical composition of  claim 1 , further comprising from about 2.5 ng to about 2.5 mg Peptide YY (PYY). 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein the PYY is PYY(3-36). 
     
     
         4 . A method of treating a metabolic disorder in a subject comprising administering a pharmaceutical composition comprising GLP-1 the tongue of the subject in a dose of from about 2.5 ng to about 2.5 mg, wherein the pharmaceutical composition provides satiation to a subject without substantially changing the concentration of GLP-1 in the plasma of the subject, and wherein the pharmaceutical composition is formulated as an oral dissolving tablet. 
     
     
         5 . The method of  claim 4 , wherein the pharmaceutical composition further comprises from about 2.5 ng to about 2.5 mg PYY. 
     
     
         6 . The method of  claim 4 , wherein the PYY is PYY(3-36). 
     
     
         7 . The method of  claim 4 , wherein the metabolic disorder is selected from the group consisting of obesity, elevated blood sugar, diabetes, fatty liver disease, high blood pressure, and polycystic ovary syndrome. 
     
     
         8 . The method of  claim 4 , wherein the pharmaceutical composition is administered to the subject before a meal.